ISP (Chile)

ISP (the Instituto de Salud Pública de Chile) is the Republic of Chile's national regulatory authority responsible for the regulation of human medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + occupational health + drugs of abuse + environmental health + public-health laboratory reference services. ISP was established by Decree-Law 2,763 of 1979 (during the Pinochet-era health-system reform that also created FONASA + ISAPRES) as a public service with administrative + financial autonomy, reporting to the Ministry of Health (MINSAL). ISP's broad mandate combines product regulation (medicines, devices, cosmetics), public-health laboratory reference services (microbiology, virology, toxicology), occupational + environmental health surveillance + drugs-of-abuse forensic services.

ANAMED (Agencia Nacional de Medicamentos) is the dedicated medicines + medical-devices regulator established within ISP by Law 20,724 of 2014 (the Pharmacy Law reform, Ley de Fármacos) + operational since 2015. ANAMED operates as a specialised agency within ISP with dedicated medicines + medical-devices regulatory functions but shares ISP's institutional + laboratory infrastructure. The ANAMED creation reflected the Chilean Government's response to a 2008-2010 generic-medicines bioequivalence + counterfeit-medicines crisis + sought to professionalise + accelerate medicines regulation while leveraging ISP's existing infrastructure.

ISP/ANAMED's organisational structure includes:

• Director Nacional del ISP — chief executive appointed by the President; serves at the discretion of the Executive.
• Subdirector Médico — deputy chief executive for medical + scientific affairs.
• Subdirector Administrativo — deputy chief executive for administrative + financial affairs.
• ANAMED (Agencia Nacional de Medicamentos) — dedicated medicines + medical-devices regulator with Sub-Departamentos for Registro Sanitario + Inspecciones + Farmacovigilancia + Control Nacional + Asuntos Regulatorios.
• Departamento Agencia Nacional de Dispositivos Médicos + Cosméticos — operates within ANAMED structure.
• Departamento de Salud Ambiental — environmental health regulation + surveillance.
• Departamento de Salud Ocupacional — occupational health regulation + surveillance.
• Departamento de Laboratorio Biomédico Nacional y de Referencia — National Reference Laboratories for microbiology, virology, parasitology, mycology, public-health toxicology, forensic toxicology, biochemistry.
• Departamento de Asuntos Científicos — scientific research + epidemiological surveillance support.
• Subdepartamento Jurídico — legal affairs + administrative enforcement + sanctions.
• Subdepartamento Internacional — international cooperation + WHO/PAHO + PIC/S + Pacific Alliance + PANDRH liaison.

ISP is distinct from + complementary to: MINSAL Subsecretaría de Salud Pública (Health Ministry Public Health Sub-Secretariat, policy + epidemiology); SAG (Servicio Agrícola y Ganadero, veterinary medicines + agricultural inputs + animal-origin foods); ACHIPIA (Agencia Chilena para la Inocuidad y Calidad Alimentaria, food safety policy coordination); the SEREMI de Salud (Regional Health Ministerial Secretariats, regional health enforcement including pharmacy practice + healthcare-facility licensing); + the Colegio de Químico Farmacéuticos de Chile (pharmacist professional body).

Legal foundations are Decree-Law 2,763 of 1979 (establishing ISP), Law 20,724 of 2014 (Ley de Fármacos I, creating ANAMED + Pharmacy Law reform), Law 21,198 of 2019 (Ley de Fármacos II, expanding pharmacy + medicines access reforms), Decree 3 of 2010 (current Chilean Pharmaceutical Products Regulation), Decree 825 of 1999 + ISP Resolution Exenta updates (current Chilean Medical Devices Regulation), Decree 977 of 1996 (Chilean Food Sanitary Regulation administered jointly with SEREMI + SAG), ISP Resolución Exenta framework + a substantial body of ISP/ANAMED technical guidelines.

ISP is a WHO/PAHO Regional Reference Authority for the Americas — designated 2011 + re-confirmed 2021 under the updated PAHO regulatory-system benchmarking using the WHO Global Benchmarking Tool framework. ISP is a PIC/S Member since 1 January 2020 + a WHO Listed Authority + an active WHO Prequalification Collaborative Registration Procedure (CRP) Reference Authority + an IMDRF Affiliate Member + an ICH Observer. ISP/ANAMED is a co-leader of the Pacific Alliance (Alianza del Pacífico) Health Regulatory Cooperation alongside INVIMA Colombia + COFEPRIS Mexico + DIGEMID Peru + an active PANDRH (Pan American Network for Drug Regulatory Harmonisation) participant alongside FDA + Health Canada + ANVISA + COFEPRIS + ANMAT + INVIMA.

Chilean pharmaceutical regulation operates under a layered framework of primary legislation + ISP Decrees + Resoluciones Exentas:

• Decree-Law 2,763 of 1979 — establishing ISP as public service with administrative + financial autonomy reporting to MINSAL.
• Sanitary Code (Código Sanitario, DFL 725 of 1968 as extensively amended) — foundational Chilean health law covering medicines, devices, food, drugs of abuse + public-health regulation.
• Law 20,724 of 2014 (Ley de Fármacos I) — Pharmacy Law reform creating ANAMED within ISP + introducing prescription-by-INN + generic-medicines bioequivalence requirements + pharmacy chain regulation.
• Law 21,198 of 2019 (Ley de Fármacos II) — Pharmacy Law reform II expanding bioequivalence + access reforms + pharmacist scope of practice.
• Decree 3 of 2010 — current Chilean Pharmaceutical Products Regulation (Reglamento de Productos Farmacéuticos de Uso Humano).
• Decree 825 of 1999 + ISP Resolución Exenta updates — current Chilean Medical Devices Regulation framework with Class I-IV risk-based classification.
• Decree 977 of 1996 — Chilean Food Sanitary Regulation administered jointly with SEREMI de Salud + SAG; ISP retains laboratory + scientific role.
• Decree 466 of 1985 — Chilean Pharmacy Premises + Pharmacy Practice Regulation.
• Decree 1876 of 1995 + Resolución Exenta 727 of 2018 — Chilean Cosmetics Regulation substantively aligned with EU Cosmetics Regulation + Pacific Alliance harmonisation.
• ISP Norma Técnica Nº 127 + Resolución Exenta 7475 of 2018 — current Chilean Good Manufacturing Practice Guidelines substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2 (updated post-PIC/S accession 2020).
• ISP Norma Técnica Nº 57 — Chilean Good Distribution Practice Guidelines substantively aligned with WHO + EU GDP.
• ISP Norma Técnica Nº 51 — Chilean Good Clinical Practice Guidelines substantively aligned with ICH E6(R2).
• ISP Resolución Exenta 381 of 2017 + 1880 of 2020 — current Chilean Pharmacovigilance framework substantively aligned with ICH E2 + EU GVP.
• Decree 405 of 1983 — Chilean Drugs of Abuse Regulation (controlled substances).
• Pacific Alliance Health Regulatory Cooperation Resolutions — directly applicable harmonised frameworks across Chile + Colombia + Mexico + Peru.

ISP operates Chile's National Reference Laboratories — one of the most comprehensive public-health laboratory networks in Latin America covering microbiology, virology, parasitology, mycology, public-health toxicology, forensic toxicology, biochemistry, pharmaceutical quality control + cosmetic quality control. The ISP laboratories serve as PAHO Regional Reference Laboratories for multiple disease + analyte categories + are pursuing WHO Prequalification of Quality Control Laboratories status for pharmaceutical QC.

• WHO Prequalification of Quality Control Laboratories Pursuit — ISP pharmaceutical QC laboratory is in the WHO Prequalification of Quality Control Laboratories pipeline; once WHO PQ-Lab designated, would join INAME Argentina + INCQS Brazil + INPM Mexico as a Latin American WHO-prequalified QC laboratory.
• ISO/IEC 17025 — ISP National Reference Laboratories are ISO/IEC 17025 accredited across multiple testing scopes including pharmaceutical chemical + microbiological + biological testing.
• PAHO Regional Reference Laboratories — ISP serves as PAHO Regional Reference Laboratory for multiple disease + analyte categories including selected vaccine-preventable diseases, foodborne pathogens, environmental toxicology.
• ISP/ANAMED regulatory laboratory — ISP conducts pre-registration quality testing + post-market surveillance testing + lot-release testing for vaccines + biologicals on behalf of ANAMED; results are direct ANAMED regulatory evidence.
• Biological characterisation — ISP conducts biological characterisation + bioequivalence assessment + biosimilar comparability assessment + bioassay development.
• Forensic toxicology — ISP operates Chile's national forensic toxicology service supporting Servicio Médico Legal (Medical Legal Service) + judicial system + counterfeit-medicine forensics.
• Public-health toxicology — ISP operates Chile's national public-health toxicology service including occupational + environmental toxicology + lead + heavy-metal surveillance + pesticide exposure surveillance.
• GMP Inspectorate base — ISP provides scientific + technical support for ANAMED GMP inspections of Chilean + foreign manufacturing facilities; ANAMED inspectors are PIC/S-trained (since 2020 Membership).
• COVID-19 + pandemic response — ISP was a central pillar of Chile's COVID-19 response including PCR + serology testing, genomic surveillance, vaccine lot release + adverse-event investigation.
• Capacity-building — ISP hosts training programmes for Latin American + Pacific Alliance pharmaceutical analysts + contributes to WHO + PAHO + Pacific Alliance regulatory-strengthening initiatives.

ISP/ANAMED medical-device + IVD regulation operates under Decree 825 of 1999 + ISP Resolución Exenta updates with a Class I-IV risk-based framework substantively aligned with GHTF/IMDRF + EU MDR. Foreign manufacturers must appoint a Chilean Authorised Representative (Titular del Registro).

• Risk-based Classification (Class I / II / III / IV) — substantively aligned with GHTF/IMDRF + EU MDR with Chilean-specific overlay; IVDs classified under separate ISP framework.
• Registro Sanitario — issued by ISP/ANAMED Departamento Agencia Nacional de Dispositivos Médicos based on technical-file review + Titular del Registro designation + Spanish-language labelling.
• Chilean Authorised Representative (Titular del Registro) — Chile-resident legal entity required for foreign manufacturers; bears post-market Tecnovigilancia responsibility + ISP/ANAMED regulatory interface.
• ISO 13485:2016 — recognised by ISP/ANAMED as QMS evidence framework; Chilean-specific overlay required including Chilean quality records + Titular QMS interface.
• Reliance pathways — ISP/ANAMED accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier + accelerates review.
• MDSAP — Chile is not currently an MDSAP Participating Regulator + does not require MDSAP audit reports; however ISP/ANAMED accepts MDSAP reports as supporting evidence + leverages MDSAP-audited manufacturer evidence in inspection planning.
• Pacific Alliance Medical Device Harmonisation — ISP/ANAMED participates in Pacific Alliance medical-device harmonisation work-streams; reliance + harmonised technical-file requirements progressively expanding across Chile + Colombia + Mexico + Peru.
• Post-market Tecnovigilancia — ISP/ANAMED operates medical-device adverse-event reporting through the Chilean Tecnovigilancia system; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Cosmetic Notification — cosmetics under Decree 1876 of 1995 + Resolución Exenta 727 of 2018 require Notificación Sanitaria + Spanish-language labelling; INCI-aligned ingredient listing + safety substantiation + cosmetovigilance reporting; Pacific Alliance Cosmetics Harmonisation progressively expanding.
• Chilean UDI — ISP/ANAMED is progressively implementing UDI requirements substantively aligned with FDA UDI + EU EUDAMED UDI; Chilean-specific overlay applies.
• Importation Permit — ISP/ANAMED Importation Permit required in addition to product registration for foreign-manufactured devices entering Chile.

ISP/ANAMED operates the Chilean Pharmacovigilance Programme under ISP Resolución Exenta 381 of 2017 + 1880 of 2020. The Chilean pharmacovigilance system integrates federal + regional + hospital + community-pharmacy + manufacturer reporting through ISP-managed online platforms + has substantial mature ADR reporting volume + leverages Chile's long-standing WHO PIDM participation since 1996.

• Programa Nacional de Farmacovigilancia — coordinated national pharmacovigilance programme with effector centres in major hospitals + SEREMI de Salud + Marketing Authorisation Holders.
• WHO PIDM Long-standing Member — Chile is a long-standing WHO Programme for International Drug Monitoring member (since 1996) + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre (UMC).
• Online ADR Reporting — ISP/ANAMED operates online ADR reporting via the RAM Online platform; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — ISP/ANAMED accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); ISP-specific submission timeline.
• Risk Management Plans (RMP) — ISP/ANAMED requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — ISP/ANAMED operates targeted active-surveillance programmes including for HIV antiretrovirals + tuberculosis + COVID-19 vaccines + biologicals + sentinel-site hospital surveillance through major Santiago + regional referral hospitals.
• ESAVI (Eventos Supuestamente Atribuibles a Vacunación e Inmunización) — Chilean vaccine adverse-event surveillance system aligned with PAHO ESAVI methodology; central to PNI safety monitoring.
• Tecnovigilancia + Cosmetovigilancia + Reactivovigilancia — ISP/ANAMED operates parallel materiovigilance for medical devices + cosmetics + IVDs.

• WHO/PAHO Regional Reference Authority — ISP is a WHO/PAHO Regional Reference Authority for the Americas (designated 2011, re-confirmed 2021); designation reflects ISP's mature regulatory system + benefits PAHO Member States through reliance pathways.
• WHO Listed Authority — ISP is a WHO Listed Authority recognised for medicines + vaccines + biologicals + WHO PQ reliance.
• WHO PQ CRP Reference Authority — ISP is one of the active WHO Prequalification Collaborative Registration Procedure (CRP) Reference Authorities in the Americas + provides reliance assessments for WHO PQ purposes.
• PIC/S Member Since 1 January 2020 — ISP/ANAMED GMP Inspectorate is a full PIC/S Member; PIC/S accession in 2020 marked a transformational maturation of Chilean GMP practice + opened reliance routes globally. ISP joined ANVISA Brazil (2021) + ANMAT Argentina (2008) as Latin American PIC/S Members.
• ICH Observer — ISP/ANAMED is an ICH Observer eligible for full Membership; ICH guidelines extensively implemented in Chilean regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• ICMRA Participant — ISP/ANAMED participates in International Coalition of Medicines Regulatory Authorities (ICMRA) Working Groups + Strategic Initiatives.
• PANDRH — ISP/ANAMED is an active PANDRH participant alongside FDA + Health Canada + ANVISA + COFEPRIS + ANMAT + INVIMA.
• Pacific Alliance Co-Leader — ISP/ANAMED is a co-leader of the Pacific Alliance (Alianza del Pacífico) Health Regulatory Cooperation Working Group alongside INVIMA Colombia + COFEPRIS Mexico + DIGEMID Peru.
• Andean Community Associate — Chile is a CAN Associate Member; ISP/ANAMED selectively engages CAN Pharmaceutical Harmonisation.
• IMDRF Affiliate — ISP/ANAMED is an IMDRF Affiliate Member + draws on IMDRF guidance for medical-device regulation.
• Bilateral MoUs — ISP/ANAMED holds MoUs with FDA + EMA + MHRA + Health Canada + TGA + PMDA + ANVISA + COFEPRIS + INVIMA + ANMAT + DIGEMID + ARCSA + AGEMED + Uruguayan MSP + Paraguayan DNVS + Spain AEMPS + Cuban CECMED + Mexican CENADIM + Australian + New Zealand + Singapore HSA + Korean MFDS.
• ICDRA — active International Conference of Drug Regulatory Authorities participant + has hosted ICDRA Regional Conferences in Santiago.
• OECD GLP MAD Participant — Chile is an OECD Mutual Acceptance of Data (MAD) Adherent + ISP participates in OECD GLP work-streams.
• APEC LSIF — ISP/ANAMED participates in Asia-Pacific Economic Cooperation Life Sciences Innovation Forum (LSIF) Regulatory Harmonisation Steering Committee.
• Industry Cooperation — ISP/ANAMED engages with Cámara de la Industria Farmacéutica de Chile (CIF) + Cámara de Innovación Farmacéutica (CIF Asilfa) + multinational industry association (Asilfa).

• Chilean Titular del Registro not properly designated — application rejected at ISP/ANAMED intake or post-approval compliance failure.
• Spanish-language labelling deficiencies — Spanish (Chilean variant) labelling + Spanish PIL (folleto de información al paciente) required; many applicants provide other Latin American Spanish variants without Chilean-specific terminology + climate-appropriate storage conditions.
• GMP Norma Técnica Nº 127 gaps — applicants assuming EU GMP / PIC/S GMP compliance is automatically sufficient without addressing Chile-specific ISP Norma Técnica Nº 127 + Resolución Exenta 7475 of 2018 clarifications + ISP-specific quality records.
• Chilean climate-zone stability data missing — Chile spans Climate Zone II (temperate central + south) + Climate Zone III (hot dry north + Atacama) + Climate Zone I (cold sub-Antarctic Patagonia); many applicants provide insufficient zonal-specific stability data.
• Bioequivalence intercambiabilidad not properly established — Law 20,724 (Ley de Fármacos I) + Law 21,198 (Ley de Fármacos II) require bioequivalence intercambiabilidad demonstration for generic medicines; bioequivalence must be conducted at ISP-recognised centres + recognised internationally.
• Pacific Alliance reliance not leveraged — Pacific Alliance Health Regulatory Cooperation underutilised by applicants targeting multiple Pacific Alliance markets through ISP + INVIMA + COFEPRIS + DIGEMID coordination.
• PANDRH reliance not leveraged — PANDRH reliance pathway underutilised by applicants targeting multiple American markets through FDA + Health Canada + ANVISA + COFEPRIS + ANMAT + INVIMA + ISP coordination.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated ISP/ANAMED CRP review; ISP is a WHO PQ CRP Reference Authority providing reliance to other regulators.
• SAG jurisdictional split — veterinary medicines + agricultural inputs + animal-origin foods sit with SAG (Servicio Agrícola y Ganadero), not ISP; avoid filing veterinary or animal-origin food applications to ISP.
• SEREMI de Salud regional scope — pharmacy practice + pharmacy premises licensing + healthcare-facility licensing sit with SEREMI de Salud (Regional Health Ministerial Secretariats), not ISP; ISP focuses on product regulation + national-laboratory functions.
• Ley Ricarte Soto pathway not leveraged — Law 20,850 of 2015 (Ley Ricarte Soto) orphan + high-cost-disease pathway substantially underutilised; provides regulatory + reimbursement coverage acceleration for eligible products.
• Variations strategy not planned — variations procedure substantively similar to WHO but with Chile-specific timelines + fee structure + Spanish-language requirements.
• Renewal timing missed — 5-year Registro Sanitario renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Clinical trial Norma Técnica Nº 51 + REC steps — Chilean clinical trials require ISP/ANAMED CTA + ISP-recognised Research Ethics Committee approval; sponsors sometimes overlook REC recognition + regional REC variations + indigenous-community consent for Chilean indigenous populations.
• Pharmacovigilance + RAM Online reporting gaps — ISP Resolución Exenta 381 of 2017 + 1880 of 2020 requirements substantively similar to ICH E2 + EU GVP but with Chile-specific RAM Online submission requirements + Spanish-language ICSR.

V5 Ultimate provides the operational infrastructure Chilean + foreign-supplier sites need for Decree-Law 2,763 of 1979 + Law 20,724 of 2014 + Law 21,198 of 2019 + Decree 3 of 2010 + ISP Norma Técnica Nº 127 GMP + ISP Medical Devices framework + Pacific Alliance + PANDRH + WHO PQ CRP + Chilean Pharmacovigilance Programme + Ley Ricarte Soto readiness.

• ISP Norma Técnica Nº 127 GMP control framework — PIC/S + EU GMP + ICH Q7-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Chile-specific clarifications + Chilean climate-zone II/III/I stability monitoring.
• ISP/ANAMED drug-registration packaging — Chilean CTD-aligned dossier structure with Chile Module 1 specifics + Module 3 stability + Chilean folleto de información al paciente + Spanish (Chilean variant) labelling + Titular del Registro declarations + Decree 3 of 2010 framework + bioequivalence intercambiabilidad evidence per Ley de Fármacos.
• Pacific Alliance workflow — Pacific Alliance Health Regulatory Cooperation packaging for joint registration across Chile + Colombia + Mexico + Peru; ISP + INVIMA + COFEPRIS + DIGEMID coordination.
• PANDRH workflow — PANDRH reliance pathway packaging for products assessed by FDA + Health Canada + ANVISA + COFEPRIS + ANMAT + INVIMA + ISP Reference Authorities.
• WHO PQ CRP workflow — ISP as WHO PQ CRP Reference Authority + applicant-side WHO PQ CRP packaging with reduced dossier + accelerated ISP/ANAMED review.
• Andean Community Associate workflow — Chile-as-CAN-Associate selective reliance packaging for CAN Member State-assessed products.
• Ley Ricarte Soto workflow — Law 20,850 of 2015 orphan + high-cost-disease pathway packaging with regulatory + reimbursement coverage acceleration.
• Chilean Titular del Registro workflow — foreign-manufacturer Titular designation + role-management + Chile-specific post-market surveillance + ISP/ANAMED interface.
• Chilean clinical-trial workflow — ISP Norma Técnica Nº 51 GCP + ISP-recognised REC + ISP-registered investigator + Chilean SUSAR reporting via RAM Online + indigenous-community consent where applicable.
• ISP/ANAMED Pharmacovigilance + RAM Online integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Spanish-language ICSR + Programa Nacional de Farmacovigilancia coordination + RAM Online submission + VigiBase upload + Risk Management Plan packaging + ESAVI vaccine adverse-event reporting.
• Tecnovigilancia + Cosmetovigilancia + Reactivovigilancia workflow — parallel materiovigilance + cosmetovigilance + IVD-vigilance packaging.
• Medical-device + cosmetic + IVD workflow — Decree 825 of 1999 + Decree 1876 of 1995 + Resolución Exenta 727 of 2018 dossier packaging + Class I-IV classification + ISO 13485 + Titular del Registro + post-market Tecnovigilancia.
• ISP/ANAMED Variations workflow — variations classification + ISP/ANAMED procedure + Chilean packaging.
• Renewal workflow — 5-year Registro Sanitario renewal window tracking + ISP/ANAMED procedure packaging.
• Pacific Alliance + PANDRH regional bridging — for companies operating across Latin America, V5 surfaces ISP + COFEPRIS + INVIMA + DIGEMID + ANVISA + ANMAT + ARCSA + AGEMED + Uruguayan MSP + Paraguayan DNVS + Cuban CECMED + Mexican CENADIM harmonised dossier-element reuse alongside national-specific extensions.